[
  {
    "ts": null,
    "headline": "Do These 3 Healthcare Stocks Need a Checkup?",
    "summary": "These three drugmakers are all well off their recent highs. Is this a sign of opportunity or risk?",
    "url": "https://finnhub.io/api/news?id=e04e817cdc30e85f467211c9ca0f7d962bb4691cc3dbcdb72f31ac9ffa69158e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764969900,
      "headline": "Do These 3 Healthcare Stocks Need a Checkup?",
      "id": 137715587,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "These three drugmakers are all well off their recent highs. Is this a sign of opportunity or risk?",
      "url": "https://finnhub.io/api/news?id=e04e817cdc30e85f467211c9ca0f7d962bb4691cc3dbcdb72f31ac9ffa69158e"
    }
  },
  {
    "ts": null,
    "headline": "Why Is Moderna (MRNA) Stock Rocketing Higher Today",
    "summary": "Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 6.4% in the afternoon session after a major long-term study from France indicated that its COVID-19 vaccine was safe and effective.",
    "url": "https://finnhub.io/api/news?id=9c26de552c533ab931ee30655fa20c0f730e5466f490e3af3399b90908fafff2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764962149,
      "headline": "Why Is Moderna (MRNA) Stock Rocketing Higher Today",
      "id": 137715777,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 6.4% in the afternoon session after a major long-term study from France indicated that its COVID-19 vaccine was safe and effective.",
      "url": "https://finnhub.io/api/news?id=9c26de552c533ab931ee30655fa20c0f730e5466f490e3af3399b90908fafff2"
    }
  },
  {
    "ts": null,
    "headline": "2 Headwinds Facing Pfizer Stock Going Into 2026",
    "summary": "There is plenty to be wary of with this drugmaker, but there are also reasons to be optimistic.",
    "url": "https://finnhub.io/api/news?id=21194e932dbfc5990f9a5c954ecb87b6a789c3a56cfe2388b8431a6ac85c354e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764948300,
      "headline": "2 Headwinds Facing Pfizer Stock Going Into 2026",
      "id": 137697221,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "There is plenty to be wary of with this drugmaker, but there are also reasons to be optimistic.",
      "url": "https://finnhub.io/api/news?id=21194e932dbfc5990f9a5c954ecb87b6a789c3a56cfe2388b8431a6ac85c354e"
    }
  },
  {
    "ts": null,
    "headline": "3 Low-Volatility Stocks with Warning Signs",
    "summary": "Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.",
    "url": "https://finnhub.io/api/news?id=2e585d93d437a9518d517d02d7c1dbf6aa2e0bb3cb72f98d3bec6748e99067ea",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764948248,
      "headline": "3 Low-Volatility Stocks with Warning Signs",
      "id": 137697222,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.",
      "url": "https://finnhub.io/api/news?id=2e585d93d437a9518d517d02d7c1dbf6aa2e0bb3cb72f98d3bec6748e99067ea"
    }
  },
  {
    "ts": null,
    "headline": "Can DefenCath Continue to Aid CorMedix's Long-Term Growth Ahead?",
    "summary": "CRMD's lead product, DefenCath, generates $167.6M in sales in the first nine months of 2025, with market exclusivity through 2033 likely to provide growth momentum.",
    "url": "https://finnhub.io/api/news?id=a83adf06cf00ee750788ad64c1550b58600fc2e54ddf76ccd5e15b65b59d6271",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764944580,
      "headline": "Can DefenCath Continue to Aid CorMedix's Long-Term Growth Ahead?",
      "id": 137697223,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "CRMD's lead product, DefenCath, generates $167.6M in sales in the first nine months of 2025, with market exclusivity through 2033 likely to provide growth momentum.",
      "url": "https://finnhub.io/api/news?id=a83adf06cf00ee750788ad64c1550b58600fc2e54ddf76ccd5e15b65b59d6271"
    }
  },
  {
    "ts": null,
    "headline": "Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson and Sanofi",
    "summary": "Eli Lilly, Johnson & Johnson and Sanofi stay in focus as Big Pharma shows signs of recovery amid innovation, M&A and easing industry pressures.",
    "url": "https://finnhub.io/api/news?id=01405f7aafe79c82bd5dae021b1f3e9c1e4d74ba98213aea0d4cd18b20ef66d5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764931320,
      "headline": "Zacks Industry Outlook Highlights Eli Lilly, Johnson & Johnson and Sanofi",
      "id": 137697022,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Eli Lilly, Johnson & Johnson and Sanofi stay in focus as Big Pharma shows signs of recovery amid innovation, M&A and easing industry pressures.",
      "url": "https://finnhub.io/api/news?id=01405f7aafe79c82bd5dae021b1f3e9c1e4d74ba98213aea0d4cd18b20ef66d5"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer: The Market Is Still Wrong About It",
    "summary": "Pfizer stock offers 30% upside with strong non-COVID franchises, margin expansion, and pipeline potential. Click here to read my latest analysis of PFE stock.",
    "url": "https://finnhub.io/api/news?id=51c99c6048860b95bef8325d506ec9210db59e19e99411baacfe06dbf9f4e9ab",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764925200,
      "headline": "Pfizer: The Market Is Still Wrong About It",
      "id": 137695812,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1292440985/image_1292440985.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Pfizer stock offers 30% upside with strong non-COVID franchises, margin expansion, and pipeline potential. Click here to read my latest analysis of PFE stock.",
      "url": "https://finnhub.io/api/news?id=51c99c6048860b95bef8325d506ec9210db59e19e99411baacfe06dbf9f4e9ab"
    }
  },
  {
    "ts": null,
    "headline": "3 Reasons PFE is Risky and 1 Stock to Buy Instead",
    "summary": "Pfizer has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 11% to $25.67 per share while the index has gained 15.3%.",
    "url": "https://finnhub.io/api/news?id=30c4e1d06eb8f15ee9ebd3e72c0bd8a8ba632ccf07b2513c09263dbd2efadd2b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764907336,
      "headline": "3 Reasons PFE is Risky and 1 Stock to Buy Instead",
      "id": 137697225,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 11% to $25.67 per share while the index has gained 15.3%.",
      "url": "https://finnhub.io/api/news?id=30c4e1d06eb8f15ee9ebd3e72c0bd8a8ba632ccf07b2513c09263dbd2efadd2b"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inc. (PFE): A Bull Case Theory",
    "summary": "We came across a bullish thesis on Pfizer Inc. on HatedMoats’s Substack. In this article, we will summarize the bulls’ thesis on PFE. Pfizer Inc.’s share was trading at $25.27 as of December 1st. PFE’s trailing and forward P/E were 14.97 and 8.50 respectively according to Yahoo Finance. Pfizer Inc. (PFE) has emerged from the post-COVID period as a transformed […]",
    "url": "https://finnhub.io/api/news?id=528b35d5797aad8c70332ed04c21b7e1b8e239aadf74eaf962f66eb673162cff",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764902890,
      "headline": "Pfizer Inc. (PFE): A Bull Case Theory",
      "id": 137692680,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "We came across a bullish thesis on Pfizer Inc. on HatedMoats’s Substack. In this article, we will summarize the bulls’ thesis on PFE. Pfizer Inc.’s share was trading at $25.27 as of December 1st. PFE’s trailing and forward P/E were 14.97 and 8.50 respectively according to Yahoo Finance. Pfizer Inc. (PFE) has emerged from the post-COVID period as a transformed […]",
      "url": "https://finnhub.io/api/news?id=528b35d5797aad8c70332ed04c21b7e1b8e239aadf74eaf962f66eb673162cff"
    }
  }
]